Highly purified cannabidiol improves stability and postural tone in adult patients with Lennox–Gastaut syndrome: A case series
Rattachement africain : it. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Lennox-Gastaut syndrome (LGS) is a severe developmental epileptic encephalopathy associated with numerous neurological signs and symptoms. Altered postural tone and the need for a caregiver-assisted wheelchair are features characterizing patients with LGS. Highly purified cannabidiol (CBD) is a novel antiseizure medication (ASM) recommended for seizure treatment, in combination with clobazam, in patients with LGS. Adding CBD to the previous ASM treatment helps in reducing seizure frequency, specifically drop seizures, in patients with LGS in both clinical trials and real-world studies. However, no data about drug effects on postural tone, motor activity, gait, and stability are available. In this case series, three adult patients diagnosed with LGS were treated with CBD as an add-on. During the follow-up, a slight improvement in seizure frequency was observed. Unexpectedly, an amelioration in postural tone and stability, measured using the validated Gross Motor Function Classification System, was also detected. Our case series suggests that CBD may help in managing patients with LGS regarding seizure control and in improving other aspects of the clinical spectrum of the disease, such as postural tone and stability. The mechanisms at the basis of this improvement may be related, other than seizure reduction, to the drug's effect on the brain locomotor centers, as demonstrated in animal model studies.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Highly purified cannabidiol improves stability and postural tone in adult patients with Lennox–Gastaut syndrome: A case series
- Date Crossref
- 01/02/2023
- Éditeur
- Wiley
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
University of Rome Tor Vergata pays non établi dans la noticeUniversité ou école supérieure
-
Department of Systems Medicine University of Rome “Tor Vergata” Rome Italy pays non établi dans la noticeUniversité ou école supérieure
-
University of Rome "Tor Vergata" Department of Systems Medicine pays non établi dans la noticeUniversité ou école supérieure
-
Epilepsy Center University Hospital of Rome “Tor Vergata” Rome Italy Neurology Unit pays non établi dans la noticeUniversité ou école supérieure
-
University Hospital of Rome "Tor Vergata" Epilepsy Center pays non établi dans la noticeUniversité ou école supérieure
-
Clinical Pharmacy University Hospital of Rome “Tor Vergata” Rome Italy pays non établi dans la noticeUniversité ou école supérieure
University of Rome Tor Vergata, Department of Systems Medicine University of Rome “Tor Vergata” Rome Italy et Department of Systems Medicine — University of Rome "Tor Vergata", avec 3 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.